How long does it take for resistance to brigatinib to develop? When drug resistance occurs, how should patients adjust their treatment plan?

Brigatinib is a second-generation ALK (anaplastic lymphoma kinase) inhibitor, mainly used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). Although the drug is excellent in overcoming resistance to crizotinib (Crizotinib), as the treatment time is prolonged, most patients may still gradually develop resistance within 1-2 years. The specific resistance time varies due to individual differences, tumor gene mutations, and treatment options.

1. Resistance mechanisms and common manifestations

The resistance mechanism of brigatinib mainly includes secondary mutations of the ALK gene (such as G1202R mutation mutation), activation of alternative pathways (such as EGFR, MET amplification), histological transformation (such as transformation into small cell lung cancer), etc. After drug resistance, patients may experience disease progression, tumor recurrence, new lesions, or even lose response to brigatinib.

2. Coping strategies after drug resistance

In the face of drug resistance, patients need to undergo genetic testing under the guidance of a doctor to clarify the resistance mechanism and adjust the treatment plan:

Replace otherALK inhibitors: If ALK resistance mutations (such as G1202R< are detected) span>), it may be necessary to switch to the third-generation ALK inhibitor lorlatinib (Lorlatinib), which has a stronger inhibitory effect on multiple drug-resistant mutations.

Combination therapy: For resistance caused by activation of the bypass pathway, it may be necessary to use a combination of EGFR, MET or MEK inhibitors to control disease progression.

Chemotherapy or immunotherapy: When targeted drugs are ineffective, patients can consider chemotherapy (such as pemetrexed+platinum regimen), or combination with immune checkpoint inhibitors (PD-1/PD-L1inhibitors).

Patients should undergo regular imaging examinations (CT, MRI), blood tests, etc. during treatment to detect drug resistance signals in a timely manner and adjust treatment plans under the guidance of doctors to extend survival and improve quality of life.

Reference materials:https://www.alunbrig.com/